• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>other >Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxide
【2h】

Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxide

机译：全反式维甲酸加化学疗法或全反式维甲酸加三氧化二砷治疗的急性早幼粒细胞白血病继发性肿瘤的发生率

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The incidence and pattern of secondary neoplasms in patients with acute promyelocytic leukemia (APL) treated with ATRA-containing regimens is not well-described. We compared secondary neoplasms in 160 patients with APL treated with ATRA plus idarubicin (n=54), or ATRA plus arsenic trioxide (ATO) (n=106) for tthe incidence of secondary cancers per unit time of follow-up. Median follow-up times for the two cohorts were 136 and 29 months, respectively. Nine patients developed secondary cancers in the chemotherapy group. These included two breast cancers, three myelodysplastic syndromes/acute myeloid leukemia, one vulvar cancer, one prostate cancer, one colon cancer and one soft tissue sarcoma. A melanoma and one pancreatic cancer developed in the ATO group. We conclude that treatment of patients with APL using the non-chemotherapy regimen of ATRA plus ATO is not associated with a higher incidence of secondary cancers (p=0.29) adjusted for unit time of exposure.
机译：含ATRA方案治疗的急性早幼粒细胞白血病（APL）患者继发性肿瘤的发生率和模式尚未得到充分描述。我们比较了160例接受ATRA加伊达比星（n = 54）或ATRA加三氧化二砷（ATO）（n = 106）治疗的APL患者每单位随访时间的继发肿瘤发生率。这两个队列的中位随访时间分别为136个月和29个月。化疗组中有9名患者发生了继发性癌症。其中包括两种乳腺癌，三种骨髓增生异常综合症/急性髓性白血病，一种外阴癌，一种前列腺癌，一种结肠癌和一种软组织肉瘤。 ATO组发生了黑色素瘤和一种胰腺癌。我们得出的结论是，使用ATRA加ATO的非化学疗法治疗APL患者与单位暴露时间调整后的继发性癌症发生率更高（p = 0.29）不相关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号